Royalty Pharma plc Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
Royalty Pharma plc (RPRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of $471.83 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2025-02-12
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was $223.25M.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was $49.96M, a 37.67% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was $123.71M, a 34.07% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was $168.33M, a 129.62% increase year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2024 was $471.83M, a 16.53% decline from fiscal 2023.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2023 was $565.25M, a 222.23% increase from fiscal 2022.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2022 was $175.42M, a 70.97% decline from fiscal 2021.
- Royalty Pharma plc other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2021 was $604.32M, a 18.31% decline from fiscal 2020.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $471.83M 10-K · filed 2025-02-12 | ||||||
| 2023-12-31 | $223.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $273.21M derived: sum of 2 quarters · filed 2025-02-12 | $396.92M derived: sum of 3 quarters · filed 2025-02-12 | $565.25M 10-K · filed 2025-02-12 | |||
| 2023-09-30 | $49.96M 10-Q · filed 2023-11-08 | $173.67M derived: sum of 2 quarters · filed 2023-11-08 | $342.01M 10-Q · filed 2023-11-08 | $176.32M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-06-30 | $123.71M 10-Q · filed 2023-08-08 | $292.05M 10-Q · filed 2023-08-08 | $126.35M derived: sum of 3 quarters · filed 2025-02-12 | $206.51M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-03-31 | $168.33M 10-Q · filed 2023-05-09 | $2.64M derived: sum of 2 quarters · filed 2025-02-12 | $82.80M derived: sum of 3 quarters · filed 2025-02-12 | $270.44M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | -$165.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$85.53M derived: sum of 2 quarters · filed 2025-02-12 | $102.11M derived: sum of 3 quarters · filed 2025-02-12 | $175.42M 10-K · filed 2025-02-12 | |||
| 2022-09-30 | $80.16M 10-Q · filed 2023-11-08 | $267.80M derived: sum of 2 quarters · filed 2023-11-08 | $341.11M 10-Q · filed 2023-11-08 | $383.84M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $187.64M 10-Q · filed 2023-08-08 | $260.95M 10-Q · filed 2023-08-08 | $303.68M derived: sum of 3 quarters · filed 2024-02-15 | $417.54M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $73.31M 10-Q · filed 2023-05-09 | $116.04M derived: sum of 2 quarters · filed 2024-02-15 | $229.91M derived: sum of 3 quarters · filed 2024-02-15 | $592.65M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | $42.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $156.60M derived: sum of 2 quarters · filed 2024-02-15 | $519.34M derived: sum of 3 quarters · filed 2024-02-15 | $604.32M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $113.87M 10-Q · filed 2022-11-08 | -$6.00M 10-Q · filed 2021-11-10 | $476.62M derived: sum of 2 quarters · filed 2022-11-08 | $561.59M 10-Q · filed 2022-11-08 | -$14.11M 10-Q · filed 2021-11-10 | $1.29B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | $362.75M 10-Q · filed 2022-08-04 | $3.23M 10-Q · filed 2021-08-11 | $447.73M 10-Q · filed 2022-08-04 | $8.11M 10-Q · filed 2021-08-11 | $1.17B derived: sum of 3 quarters · filed 2023-02-15 | $1.18B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | $84.98M 10-Q · filed 2022-05-05 | $809.70M derived: sum of 2 quarters · filed 2023-02-15 | $813.47M derived: sum of 3 quarters · filed 2023-02-15 | $811.85M derived: sum of 4 quarters · filed 2023-02-15 | |||
| 2020-12-31 | $724.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $728.49M derived: sum of 2 quarters · filed 2023-02-15 | $726.87M derived: sum of 3 quarters · filed 2023-02-15 | $739.79M 10-K · filed 2023-02-15 | |||
| 2020-09-30 | $3.77M 10-Q · filed 2021-11-10 | $2.14M derived: sum of 2 quarters · filed 2021-11-10 | $15.06M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$1.62M 10-Q · filed 2021-08-11 | -$11.30M 10-Q · filed 2021-08-11 | |||||
| 2019-12-31 | $112.88M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |